Diabetes technology section
Sontra's continous non-invasive glucose monitor, the Symphony™ Diabetes Management System, is being co-developed with Bayer Diagnostics. Their glucose monitor measures glucose diffusing through ultrasonically permeated skin continously for up to twenty four hours. The product consists of SonoPrep instrument, a glucose biosensor patch with RF transmitter and a glucose meter .
Sentek Group, Inc. is developing a non-invasive diagnostic tool targeting diabetes patients that uses a patented Crystalline Colloidal Array (CCA) technology exclusively licensed from the University of Pittsburgh. While Sentek plans to exploit several applications of the technology, the company’s first commercial efforts are for the Glucoview ocular insert that will enable diabetics to continuously monitor their blood glucose levels, and unlike most competing technologies, it will not require finger stabs.
Since 1995, Sensys Medical, Inc., formerly Instrumentation Metrics, has been focused on advancing technology for non-invasive blood glucose monitoring. The Company intends to commercialize a device that will dramatically advance the practice of blood glucose monitoring and the science of diabetes disease management.
Senseonics Inc (formerly Sensors for Medicine and Science or SMSI until 2012), based in Germantown, MD, is developing a fully implantable continuous glucose monitoring system that uses fluorescence sensing technology. Their goal is to improve accuracy, ease of use and sensor life to make glucose management better.
OrSense Ltd. is a medical device company based in Israel. Their first product, the NBM 200MP is based on its proprietary Occlusion Spectroscopy technology. Orsense claims this technology overcomes obstacles that have plagued other companies attempting to measure glucose optically through the skin.
Optiscan, a privately-held company in Hayward, California, has developed a continuous bedside glucose monitoring system called the OptiScanner. It is currently being developed for use with terminally ill patients.